PCRX:NASDAQPacira BioSciences, Inc. Analysis

Pacira BioSciences delivered a solid top‑line performance in Q1 2026, posting total revenue of $177 million, a 5% YoY increase driven by 7% volume growth of EXPAREL and continued uptake of ZILRETTA and iovera. Forward earnings are projected at $3.64 per share, slashing the forward P/E to roughly 6.2 versus a current trailing P/E of 174, which dwarfs the industry average of 27.2. The DCF‑derived fair value of $34.98 suggests the stock trades at a ~29% discount to intrinsic value, while the market price of $22.62 sits just above the technical support of $22.17. Analyst sentiment remains positive, with a consensus “buy” rating and a median price target of $27.
On the technical front, the 20‑day SMA (24.03) sits above the 50‑day (23.52) and 200‑day (23.71) averages, and the price is currently below all three, indicating short‑term bearish pressure. MACD is in a bearish divergence and RSI at 41 signals neutral momentum, while volatility remains high at 35% over the past 30 days. Despite decreasing volume, the low beta of 0.47 points to limited market‑wide risk, and the company’s cash position ($202 million) comfortably exceeds its debt ($411 million) after accounting for a moderate debt‑to‑equity ratio.